Celldex Therapeutics, Inc. — Investor Relations & Filings

Celldex Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies. The company's research focuses on the intersection of mast cell biology and immunology to treat severe inflammatory, allergic, and autoimmune diseases. Its lead program is barzolvolimab, a humanized monoclonal antibody that inhibits KIT, a receptor tyrosine kinase essential for the function and survival of mast cells. By targeting this core pathological driver, Celldex aims to provide a best-in-class treatment option. The company leverages proprietary antibody programs and technologies supported by in-house discovery and development capabilities to advance its pipeline.